# Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma

> **NCT01099722** · PHASE3 · COMPLETED · sponsor: **Mundipharma Research Limited** · enrollment: 261 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Flutiform
- **DRUG:** Symbicort Turbohaler

## Key facts

- **NCT ID:** NCT01099722
- **Lead sponsor:** Mundipharma Research Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-11
- **Final completion:** 2011-07
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01099722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01099722, "Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01099722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*